Erectile dysfunction (ED) is increasingly considered as one manifestation of systemic vascular disease. Accordingly, ED and coronary artery disease share mutual risk factors and frequently coexist. Sexual health is an important aspect of our patients' lives, and ED is a common concern of the cardiovascular patient. Despite this, sexual function is under-addressed in the cardiac patient. Even when this topic is broached by the primary care physician or urologist, ED frequently remains untreated due to safety concerns involving cardiac disease and other comorbidities. This article describes our experience with this unique patient population, as well as our approach to building a multidisciplinary clinic designed to specifically address the important issue of ED in the cardiac patient.
Introduction
There is a close link between male erectile dysfunction (ED) and cardiac disorders, primarily based on the potential vasculogenic origin of both conditions. The following article reviews recently published data on the connection between cardiovascular disorders and sexual dysfunction. In addition, a cohort comparison regarding the occurrence of ED among small groups of consecutively seen nonselected patients in a cardiology outpatient setting between different geographical and socio-cultural regions is presented. Owing to the growing importance of sexual problems in the daily cardiology patient cohort, we describe our new multidisciplinary approach for high-risk patients with ED, followed by an overview of currently available treatment options for ED in patients with underlying cardiovascular disorders.
Erectile dysfunction and cardiac disease
Numerous studies have shown that ED shares several modifiable risk factors with cardiovascular disease including atherosclerosis, 1 hypertension, hyperlipidemia, diabetes mellitus, 2 smoking, 3 obesity and sedentary lifestyle. 4 More specific data are difficult to obtain due to concomitant presence of more than one risk factor in most of the patients diagnosed with ED. Data from several studies involving patients with cardiac disease have shown a high prevalence, 42-75%, of ED in this patient population. [5] [6] [7] In addition, ED is even discussed to serve as an early marker for vascular disorders: Kaiser et al 1 demonstrated that the presence of arteriogenic ED (using penile Doppler ultrasonography) was associated with a high prevalence of clinically apparent atherosclerosis, particularly in men aged 450 y. Greenstein et al 8 also reported a significant correlation between ED and the number of occluded coronary arteries. Other investigators have found incidence rates of occult cardiovascular disease in men with ED as high as 15-30%. 9, 10 Endothelial dysfunction appears to play a common role in both ED and coronary artery disease. Alterations in the endothelial L-arginine-NO-mediated smooth muscle relaxation pathway have been demonstrated in atherosclerotic coronary arteries of humans and animal models.
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Arterial insufficiency
There is now a general agreement that the majority of cases of ED are vasculogenic in nature. Moreover, in patients with underlying cardiovascular disorders, vascular causes play an even larger role in the concomitant development of ED. Vasculogenic causes of ED are common, and can be subdivided into arterial insufficiency and endothelial dysfunction. Atherosclerosis accounts for approximately 40% of ED in men 450 y of age, 1 and is at least in part due to reduced arterial inflow into the penile corpora cavernosa. 13 Endothelial dysfunction appears to be a systemic phenomenon, affecting both the coronary and peripheral circulation. Studies to establish whether basal NO production is altered in HF patients have yielded conflicting results. [14] [15] [16] It has been suggested that endothelial damage could result in a reduction in the availability of endothelium-derived NO from either decreased production or increased breakdown. In addition, atherosclerosis might alter the L-Arginine-NO pathway, decreasing NO production. 11, 12 Oxygen-derived free radicals have also been associated with inhibition of endothelium-dependent vasodilation, suggesting that rapid inactivation of NO may be caused by increased free radical production. 17 Other possible mechanisms of endothelial dysfunction include cell surface receptor abnormalities or alterations at the G protein level, which may account for decreased efficacy of free NO, as seen in atherosclerosis. 18 Effects of commonly used drugs in patients with cardiovascular disorders on sexual function Beta-adrenergic receptor blockers, commonly used for the treatment of hypertension, coronary artery disease and heart failure, are known for their negative effects on male sexual function. 19 Theories point to adverse effects of decreased perfusion pressure or a direct (but unknown) effect on smooth muscle. Support for the latter mechanism is derived from the observation that despite pressure-lowering effects, treatment with alpha-adrenergic receptor blockers is not associated with ED, and that this class of medications may actually improve preexisting sexual dysfunction. 20 In particular, atenolol, 21 propranolol 22 and metoprolol 23 have been associated with ED, but some reports reveal negative effects with most, if not all betaadrenergic beta-receptor blockers. It is also believed that beta-blockers can cause (or worsen) depression, and depression itself might also play a role for the occurrence of ED; however, there is controversy and clinical trials do not support this hypothesis. 24 While sexual disorders caused by diuretics have been reported, the mechanism remains ill-defined. 19 10-20% of patients taking thiazide diuretics may experience a decline in sexual function. 25 The impact of ACE inhibitors and ARBs on ED is unclear. Croog et al 22 found that the ACE inhibitor captopril actually enhances sexual function. Interestingly, if ACE-inhibitor therapy (eg for the treatment of heart failure) is associated with an improved functional cardiac status, this might result in improved sexual function, 26 at least, in a subset of patients. Controversy exists about the effects of calcium channel blockers and ARBs and their potential to worsen sexual function. A Japanese study reported that in hypertensive patients switched from calcium channel blockers to candesartan therapy, patients o65 y of age experienced improved sexual function. 27 Improvement also has been shown by using losartan 28 and valsartan. 29 
Sexual function in cardiac patients
The effects of a significant cardiac condition on the vitality of a patient's sex life have not been elaborately explored. There are, however, some small studies demonstrating a general deterioration in this aspect of a patient's life after experiencing a cardiac event.
After myocardial infarction (MI), only two-thirds of male patients returned to satisfying sexual relations within 6 weeks, with 90% achieving at least pre-MI levels of sexual function by 1 year. Importantly, most of the patients also experience a decrease in frequency of sexual relations. [30] [31] [32] Female patients who were studied a mean of 18 months post-MI reported slightly lower rates of return, with only 73% having resumed sexual relations with their husbands. 33 In a study by Papadopoulos et al, 34 134 patients were interviewed about the impact of cardiovascular (bypass) surgery on their sexuality; 39% of patients reported decreased frequency of sexual activity, with 17% of patients and 35% of their partners expressing fear of resuming sexual activity.
'Real numbers' of ED in nonselected consecutive patients in a routine cardiology clinic
In a prospective manner, we addressed the incidence of sexual dysfunction/ED among a relatively small group of consecutive patients in our cardiac outpatient clinic among new clinic patients with a history of cardiovascular disorders who appeared for a routine outpatient first visit. These data were compared with a similar survey performed by the first author during his clinical work in a Western European hospital and a hospital in the Middle East in order to compare socio-cultural differences in the clinical approach to patients with ED, and from patients towards their physician. These data are presented in Figures 1-3 . Assessing a small group of 18-22 consecutive patients for routine cardiology visits would imply a 50-60% incidence of ED based on published data from the Massachusetts Male Aging study. 35 Interestingly, the number of patients addressing ED during their first visit towards their cardiologist is very small (o10%, Figure 1 ). However, once the physician addressed the problem of potential ED, a higher than estimated number of patients admitted ED and talked about it with their cardiologist, at least in the US and in Europe, whereas in the Middle East only 50% of estimated affected patients did. Even though this suggested (within this small cohort) a lower number of ED among patients with cardiovascular disorders, it turned out that almost B70% of these patients had been taking medication to improve sexual function before, and there was no difference between the clinic settings in the US, Western Europe or the Middle East (Figure 2) .
Looking within the US hospital settings at differences in ethnic distribution about ED revealed that the majority of African American and Caucasian patients with cardiovascular disorders admitted ED, whereas only 50% of patients of Hispanic origin reported ED (Figure 3 ). This could imply a lower number of ED in this small cohort of hispanic patients compared to Caucasians and African Americans, or, just a higher threshold to openly talk about ED among the hispanic patient population.
These data are subjective, derived nonrandomized in a very small group of consecutive new patients seen in an outpatient clinic setting and therefore do not necessarily represent any population or ethnic group in general. However, it unanimously shows that ED seems to be an enormous problem with a higher than usual incidence among patients with a cardiovascular history, and that the threshold to talk to a physician or, in particular, to a cardiologist about ED is relatively high for most patients, even though treatment is sought.
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with underlying cardiovascular disorders. However, it is surprising that neither cardiologists nor vascular specialists pay much attention to ED in their patients. Owing to an internal questionnaire, we evaluated the following reasons for this: (1) patients do not consider their cardiologist as a specialist for the treatment of ED; (2) patients report mainly vital or cardiac-related complaints such as chest pain, shortness of breath, or fatigue (even though new onset of ED in most cases is even more irritating than several purely cardiac or vascular concerns in many patients); (3) most cardiologists or vascular specialists do not actively inquire about sexual function or dysfunction in their patients (it is not their main focus of interest and requires not only extra time but also a very sensitive approach, which seems to make several physicians as well as patients uncomfortable). In our own experience, the majority of patients with underlying cardiovascular disorders are not treated for their ED; moreover, in several cases, treatment was refused by the patients' primary care physicians (or their urologists) as assessed from a patient questionnaire. The reasons stated for that were concomitant cardiac medication and/or their cardiovascular history. In order to specifically assess the possibilities of potential adequate treatment for ED in (hemodynamically stable) patients with underlying cardiovascular disorders, we created a multidisciplinary approach especially for patients with ED considered at high risk (because of their cardiovascular history and complaints). In this multidisciplinary approach, a cardiologist, an urologist, a psychiatrist, and a vascular specialist (in our case, a vascular surgeon) came together to develop an initial assessment program for these patients. The program consists of 10 steps, called the Sex and the Heart evaluation ( Figure 4) . Each of the 10 steps results in a cumulative point scale, which translates into a total (risk) score to assess treatment options. The system in its entirety will be described elsewhere. In brief, the evaluation and possible treatment options contain the following: Step I 1.
S exual performance description (talk)
2.
E valuation of potential causes (drugs)
3. EX ercise capacity (stress test) 4.
a ssessment of contributing factors 5.
t eam approach (PUPSTC)
Step II 6.
Control concomittant H ealth conditions 7.
Optimize E F
8.
A ugment perfusion (vascular ED)
9.
Reduce R isk factors 10.
Follow-up + alternate T herapy Figure 4 A stepwise approach to comprehensive patient evaluation in a multidisciplinary clinic designed to assess and potentially treat erectile dysfunction in 'high-risk' patients with multiple cardiovascular comorbidities.
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PDE-5 inhibitor therapy might be required in individual patients. In unsuccessful cases, alternative treatment options should be considered. In contrast to the multidisciplinary approach for the initial assessment, follow-up is scheduled by one practitioner, which is either the patient's PCP or the cardiologist or the urologist, owing to the primary problem or primary treatment plan. The medical treatment options are listed below.
Cardiovascular-directed approach to patients with ED
As stated above, after initial evaluation, the management for patients with ED should include optimization of cardiac function, in particular, in patients with known left ventricular dysfunction or heart failure, according to ACC/AHA guidelines. In individual cases, regional perfusion assessment might reveal stenoses of the common iliac, hypogastric or the pudendal arteries. Even though not widely studied, percutaneous balloon dilatation or penile surgical revascularization procedures can result in improvement of sexual dysfunction in some, but not all cases of ED. In patients with a medication regimen consisting of drugs with ED side effects, exchange for more favorable drugs might be considered, for example, exchange from beta-blockers to ARBs in hypertensive patients, if clinically possible. If depression appears to play a major role in the occurrence of ED, adequate treatment might not only improve depression but also ED. Unfortunately, however, many antidepressants themselves can cause or worsen ED. Finally, all cardiovascular risk factors should be avoided or, if possible, at least controlled. In patients considered at high risk because of their underlying cardiovascular disorders, only addressing the above, specific ED treatment might be considered.
Oral phosphodiesterase inhibitors
In March 1998, sildenafil citrate (Viagra s ) became the first approved oral drug for ED in the US. Sildenafil and other PDE-5 inhibitors enhance cGMP-NO-mediated vasodilatation. Detumescence occurs when type 5 phosphodiesterase catabolizes cGMP, accompanied by NO depletion and restoration of penile vascular tone. PDE-5 inhibitors thereby increase both the number and duration of erections in men. 36 In a quantitative meta-analysis of 27 trials in 6659 men with ED, a higher percentage of successful sexual intercourse was achieved with sildenafil compared with placebo (57 versus 21%, respectively). 37 Patient education is critical for optimal response to sildenafil. This includes informing the patient to take the medication on an empty stomach and to time sexual activity so that it occurs within one to 6 h after intake. Peak serum concentration occurs at 1 h, and drug half-life is 4-5 h. 38 Vardenafil (Levitra s ) and tadalafil (Cialis s ) are newer phosphodiesterase inhibitors which appear to be as effective as sildenafil. 39, 40 Tadalafil has a longer duration of action proposing the hypothetical advantage of allowing more spontaneity in sexual activity. Like sildenafil, they both also potentiate the hypotensive response to nitrates. Therefore, all PDE-5 inhibitors are contraindicated with concomitant nitrate or any NO donor use (nitroprusside, nitroglycerine, molsidomin). 41 Although these newer agents may not have additional cardiac risks than sildenafil, there is less clinical information available related to the safety of the agents in patients with heart disease.
Other oral drug therapy for ED
Other oral drugs for treatment of ED are apomorphine (Apokyn s ) and yohimbine (Yocon s ). Apomorphine is centrally acting and has shown mild clinical efficacy in treatment of ED; 42 currently, it is not available in the US but in several European and Middle Eastern countries. Yohimbine is an alpha-2 receptor blocker with limited efficacy in the treatment of ED. 43 It should be used with caution because of its cardiovascular side effects, including tachycardia and the potential for hypertension. Despite aggressive marketing, no data to support the assertion that nutritional supplements, herbal therapy, or vitamins have proved beneficial effect in the treatment of ED. 44 
Hormonal therapy in ED
Treatment of hypogonadism results in reliable improvement in the symptoms of diminished libido and feelings of enhanced sexuality. Androgen replacement transdermally applied therefore can improve sexual function. 45 However, pure vasculogenic ED may not respond as well, particularly in older men, due to coexisting vascular pathology and, in particular, if hormonal insufficiency is not the main reason for ED.
Invasive treatment modalities in ED
Penile injections with vasoactive medications are effective in 70-80% of patients, have an onset of action within ten minutes and are relatively painless. 46 They are used by approximately 10% of patients with ED, and are the most common treatment for men who take nitrates or those who have had no success with phosphodiesterase inhibitors. Alprostadil is most frequently used. The overall risk is relatively low: there has only been one case report of MI temporally associated with alprostadil penile injection. There is no cardiovascular contraindication to its use, 47 unless the patient is on chronic anticoagulation, which increases injection-induced bleeding risk.
Intraurethral suppositories of alprostadil avoid penile injection but are less effective. This technique requires the use of a tourniquet at the base of the penis for optimal results. 48 Initial treatment should occur in a health care or monitored environment owing to the rare occurrence of syncope.
Mechanical devices for ED therapy
Vacuum constriction devices offer a noninvasive mechanical treatment and are used worldwide by approximately 5% of men with ED. 49 A plastic cylinder is placed around the penis that draws blood into the penis by creating negative pressure. A tourniquet is placed at the base of the penis once adequate rigidity is attained; trapping blood within the corpora cavernosa.
Surgical implants remain a successful and satisfying treatment for men whose condition has failed oral therapy and find other treatment options unsatisfactory. 50 Nevertheless, the number of procedures performed is relatively low compared with the estimated population with ED. The primary risks are mechanical device failure (2% at 2 years; 14% at 5 years) and infection in 2-3% of cases. 50, 51 In particular, in patients with a cardiac history or known vascular disorders and concomitant associated higher operative risks, most urologists do not recommend device implantation. This also represents the last resort of ED treatment, since it excludes all other treatment options and therefore should be reserved for only a highly selected group of patients who failed all other treatment options, after minimizing all surgical risks.
Conclusion
ED is highly prevalent among patients with cardiovascular disorders. Unfortunately, most cardiovascular specialists do not address sexual problems with their patients during routine visits, even though the majority of patients with underlying cardiovascular disorders suffer from ED. On the other hand, most cases of ED are vasculogenic in nature, thus requiring special attention by a (cardio-) vascular specialist. A broader than formerly recommended 52 multidisciplinary approach by a cardiologist, urologist and psychiatrist is recommended to evaluate high-risk patients with ED. Treatment options include improvement of cardiac function and regional perfusion, lowering cardiovascular risks, exchanging medication with unfavorable side effects for sexual function, treating concomitant depression, and trial of PDE-5 inhibitors.
